Absci Corporation

Ladies and gentlemen, thank you for standing by. My name is Duncan and I will be your conference operator for today. I would like to welcome you to ABSEI First Quarter 2026 Business Update. All lights have been placed on mute to prevent any background noise. And after the speaker's remarks, there will be a question and answer session. Now, I'd like to turn over the conference over to Alex Khan. Please go ahead.

Thank you. Earlier today, Abcide released financial and operating results for the quarter ended March 31st, 2026. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an email to investors at Abcide.com. An archived webcast of this call will be available for replay on Abcide's investor relations website at investors.abcide.com for at least 90 days after this call. Joining me today are Sean McLean, Abcide's founder and CEO, Zach Donison, Chief Financial Officer and Chief Business Officer, and Ransi Somaratne, Chief Medical Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. These include statements regarding the development and clinical progress of our pipeline programs, including ABS-201, the design, enrollment, conduct, and timelines of our ongoing Phase I-IIA headline trial of ABS-201 for anterior neck alopecia, Anticipated timing of an interim proof of concept data readout for ABS-201 in the second half of 2026. The potential advancement of ABS-201 into Phase III development. Anticipated initiation of a Phase II clinical trial of ABS-201 for endometriosis in fourth quarter of 2026. And a potential proof of concept readout in the second half of 2027. The anticipated characteristics and product profile of ABS-201 as a drug product. Our target product profile and its attributes. The potential for an expedited development pathway, including the possibility of advancing directly from Phase I to Phase III. Our plan engagement with the FDA regarding development strategy. and the potential market opportunity and commercial prospects for ABS-201. Certain statements may also include projections regarding potential market opportunity. These estimates are based on various assumptions, including potential regulatory approval, the final approved label, and the evolving competitive landscape, any of which could cause our actual addressable market to differ materially for these projections. In addition, certain research findings discussed today reflect participant responses to a hypothetical product profile and do not represent clinical results for ABS-201. Additional information regarding the risks and uncertainties, the code effect, or forward-looking statements is set forth in the press release of AFSCI Issue Today, our most recent annual report on Form 10-K, and subsequent documents and reports filed by AFSCI from time to time with the FCC. If said was required by law, AFSCI disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, either because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, May 7th, 2026.

With that, I'll turn the call over to Sean. Thanks, Alex. Good afternoon, everyone. Thanks for joining us. Today, I'll cover three things.